Merck Germany Reports 5% Decline In Q2 Sales, Expects More Decline In 2023
Portfolio Pulse from Vandana Singh
Merck KGa Germany reported a 4.8% decline in Q2 sales to €5.3 billion. Despite strong growth in the Healthcare sector, Group EBITDA pre declined by 12.8% to €1.55 billion due to decreased sales volumes and lower share of higher-margin products. The company has updated its 2023 forecast, expecting an organic sales growth of -2% to +2% and an organic decline in EBITDA pre by -9% to -3%. Both net sales and EBITDA pre are likely to be impacted by negative foreign exchange effects.
August 04, 2023 | 1:45 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Merck KGa Germany reported a decline in Q2 sales and expects further decline in 2023. This could negatively impact the stock price.
The company reported a decline in sales and expects further decline in the future. This could lead to a decrease in investor confidence and a potential drop in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
NEGATIVE IMPACT
Merck KGa Germany reported a decline in Q2 sales and expects further decline in 2023. This could negatively impact the stock price.
The company reported a decline in sales and expects further decline in the future. This could lead to a decrease in investor confidence and a potential drop in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100